Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
Autor(a) principal: | |
---|---|
Data de Publicação: | 2007 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
dARK ID: | ark:/48912/001300000ms76 |
DOI: | 10.1128/JCM.02368-06 |
Texto Completo: | http://dx.doi.org/10.1128/JCM.02368-06 http://repositorio.unifesp.br/handle/11600/29521 |
Resumo: | Dalbavancin is a lipoglycopeptide antimicrobial agent with a potency significantly better than that of vancomycin when tested against staphylococci and streptococci. These two pathogens are common causes of skin and skin structure infections (SSSIs), and dalbavancin has been approved for the treatment of moderate to severe SSSIs. This study generated susceptibility data for staphylococci and beta-hemolytic streptococci from 52 U.S. medical centers that locally tested dalbavancin, vancomycin, and other antimicrobial class representatives to assess the potency of dalbavancin and the overall contemporary activities of commonly prescribed agents. Locally generated data showed that oxacillin-resistant staphylococci (57.0% overall) had slightly higher dalbavancin MIC,0 values (0.19 mu g/ml) than oxacillin-susceptible strains (0.125 mu g/ml). This potency was 8- to 16-fold greater than that for vancomycin. P-Hemolytic streptococci had MIC90 values ranging between <= 0.016 and 0.064 mu g/ml (highest for group B isolates). Levofloxacin, gentamicin, and tetracycline were active against oxacillin-susceptible staphylococci (82 to 99% susceptible), with lower susceptibility rates seen for the oxacillin-resistant strains. Linezolid coverage was > 98% against staphylococci. Erythromycin resistance was high for staphylococci (30.6 to 94.1%) with inducible clindamycin resistance rates of 26.0% and 55.0% for oxacillin-susceptible and -resistant Staphylococcus aureus, respectively. beta-Hemolytic streptococci had a 20.2% erythromycin resistance rate and a 60% inducible clindamycin resistance rate but were highly susceptible to other tested agents. Etest reading errors were apparent and skewed results towards slightly higher dalbavancin MICs, requiring further education on how to interpret Etest method results for this compound. Current disk diffusion breakpoint criteria for oxacillin susceptibility for S. aureus showed a very-major-error rate of 2.3% and only a 0.9% minor-error rate when cefoxitin was used to predict oxacillin susceptibility. Dalbavancin demonstrated excellent potency and activity (100% susceptibility at proposed breakpoints) against common causes of SSSI pathogens in this U.S. multicenter study sample. |
id |
UFSP_7f92f1eb0f49cb09878c6910bf7a3527 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/29521 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United StatesDalbavancin is a lipoglycopeptide antimicrobial agent with a potency significantly better than that of vancomycin when tested against staphylococci and streptococci. These two pathogens are common causes of skin and skin structure infections (SSSIs), and dalbavancin has been approved for the treatment of moderate to severe SSSIs. This study generated susceptibility data for staphylococci and beta-hemolytic streptococci from 52 U.S. medical centers that locally tested dalbavancin, vancomycin, and other antimicrobial class representatives to assess the potency of dalbavancin and the overall contemporary activities of commonly prescribed agents. Locally generated data showed that oxacillin-resistant staphylococci (57.0% overall) had slightly higher dalbavancin MIC,0 values (0.19 mu g/ml) than oxacillin-susceptible strains (0.125 mu g/ml). This potency was 8- to 16-fold greater than that for vancomycin. P-Hemolytic streptococci had MIC90 values ranging between <= 0.016 and 0.064 mu g/ml (highest for group B isolates). Levofloxacin, gentamicin, and tetracycline were active against oxacillin-susceptible staphylococci (82 to 99% susceptible), with lower susceptibility rates seen for the oxacillin-resistant strains. Linezolid coverage was > 98% against staphylococci. Erythromycin resistance was high for staphylococci (30.6 to 94.1%) with inducible clindamycin resistance rates of 26.0% and 55.0% for oxacillin-susceptible and -resistant Staphylococcus aureus, respectively. beta-Hemolytic streptococci had a 20.2% erythromycin resistance rate and a 60% inducible clindamycin resistance rate but were highly susceptible to other tested agents. Etest reading errors were apparent and skewed results towards slightly higher dalbavancin MICs, requiring further education on how to interpret Etest method results for this compound. Current disk diffusion breakpoint criteria for oxacillin susceptibility for S. aureus showed a very-major-error rate of 2.3% and only a 0.9% minor-error rate when cefoxitin was used to predict oxacillin susceptibility. Dalbavancin demonstrated excellent potency and activity (100% susceptibility at proposed breakpoints) against common causes of SSSI pathogens in this U.S. multicenter study sample.JMI Labs, Beaver Kreek Ctr 345, N Liberty, IA 52317 USAUniversidade Federal de São Paulo, São Paulo, BrazilTufts Univ, Sch Med, Boston, MA 02111 USAUniversidade Federal de São Paulo, São Paulo, BrazilWeb of ScienceAmer Soc MicrobiologyJMI LabsUniversidade Federal de São Paulo (UNIFESP)Tufts UnivBiedenbach, Douglas J.Ross, James E.Fritsche, Thomas R.Sader, Helio S. [UNIFESP]Jones, Ronald N.2016-01-24T12:41:54Z2016-01-24T12:41:54Z2007-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion998-1004application/pdfhttp://dx.doi.org/10.1128/JCM.02368-06Journal of Clinical Microbiology. Washington: Amer Soc Microbiology, v. 45, n. 3, p. 998-1004, 2007.10.1128/JCM.02368-06WOS000245071500045.pdf0095-1137http://repositorio.unifesp.br/handle/11600/29521WOS:000245071500045ark:/48912/001300000ms76engJournal of Clinical Microbiologyinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-31T05:04:15Zoai:repositorio.unifesp.br/:11600/29521Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-12-11T20:25:49.428825Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States |
title |
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States |
spellingShingle |
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States Biedenbach, Douglas J. Biedenbach, Douglas J. |
title_short |
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States |
title_full |
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States |
title_fullStr |
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States |
title_full_unstemmed |
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States |
title_sort |
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States |
author |
Biedenbach, Douglas J. |
author_facet |
Biedenbach, Douglas J. Biedenbach, Douglas J. Ross, James E. Fritsche, Thomas R. Sader, Helio S. [UNIFESP] Jones, Ronald N. Ross, James E. Fritsche, Thomas R. Sader, Helio S. [UNIFESP] Jones, Ronald N. |
author_role |
author |
author2 |
Ross, James E. Fritsche, Thomas R. Sader, Helio S. [UNIFESP] Jones, Ronald N. |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
JMI Labs Universidade Federal de São Paulo (UNIFESP) Tufts Univ |
dc.contributor.author.fl_str_mv |
Biedenbach, Douglas J. Ross, James E. Fritsche, Thomas R. Sader, Helio S. [UNIFESP] Jones, Ronald N. |
description |
Dalbavancin is a lipoglycopeptide antimicrobial agent with a potency significantly better than that of vancomycin when tested against staphylococci and streptococci. These two pathogens are common causes of skin and skin structure infections (SSSIs), and dalbavancin has been approved for the treatment of moderate to severe SSSIs. This study generated susceptibility data for staphylococci and beta-hemolytic streptococci from 52 U.S. medical centers that locally tested dalbavancin, vancomycin, and other antimicrobial class representatives to assess the potency of dalbavancin and the overall contemporary activities of commonly prescribed agents. Locally generated data showed that oxacillin-resistant staphylococci (57.0% overall) had slightly higher dalbavancin MIC,0 values (0.19 mu g/ml) than oxacillin-susceptible strains (0.125 mu g/ml). This potency was 8- to 16-fold greater than that for vancomycin. P-Hemolytic streptococci had MIC90 values ranging between <= 0.016 and 0.064 mu g/ml (highest for group B isolates). Levofloxacin, gentamicin, and tetracycline were active against oxacillin-susceptible staphylococci (82 to 99% susceptible), with lower susceptibility rates seen for the oxacillin-resistant strains. Linezolid coverage was > 98% against staphylococci. Erythromycin resistance was high for staphylococci (30.6 to 94.1%) with inducible clindamycin resistance rates of 26.0% and 55.0% for oxacillin-susceptible and -resistant Staphylococcus aureus, respectively. beta-Hemolytic streptococci had a 20.2% erythromycin resistance rate and a 60% inducible clindamycin resistance rate but were highly susceptible to other tested agents. Etest reading errors were apparent and skewed results towards slightly higher dalbavancin MICs, requiring further education on how to interpret Etest method results for this compound. Current disk diffusion breakpoint criteria for oxacillin susceptibility for S. aureus showed a very-major-error rate of 2.3% and only a 0.9% minor-error rate when cefoxitin was used to predict oxacillin susceptibility. Dalbavancin demonstrated excellent potency and activity (100% susceptibility at proposed breakpoints) against common causes of SSSI pathogens in this U.S. multicenter study sample. |
publishDate |
2007 |
dc.date.none.fl_str_mv |
2007-03-01 2016-01-24T12:41:54Z 2016-01-24T12:41:54Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1128/JCM.02368-06 Journal of Clinical Microbiology. Washington: Amer Soc Microbiology, v. 45, n. 3, p. 998-1004, 2007. 10.1128/JCM.02368-06 WOS000245071500045.pdf 0095-1137 http://repositorio.unifesp.br/handle/11600/29521 WOS:000245071500045 |
dc.identifier.dark.fl_str_mv |
ark:/48912/001300000ms76 |
url |
http://dx.doi.org/10.1128/JCM.02368-06 http://repositorio.unifesp.br/handle/11600/29521 |
identifier_str_mv |
Journal of Clinical Microbiology. Washington: Amer Soc Microbiology, v. 45, n. 3, p. 998-1004, 2007. 10.1128/JCM.02368-06 WOS000245071500045.pdf 0095-1137 WOS:000245071500045 ark:/48912/001300000ms76 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Journal of Clinical Microbiology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
998-1004 application/pdf |
dc.publisher.none.fl_str_mv |
Amer Soc Microbiology |
publisher.none.fl_str_mv |
Amer Soc Microbiology |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1822183934336696320 |
dc.identifier.doi.none.fl_str_mv |
10.1128/JCM.02368-06 |